Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The diltiazem-digoxin interaction.

H Rameis, D Magometschnigg, U Ganzinger

    Clinical Pharmacology and Therapeutics
    |August 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    The calcium channel blocker diltiazem increases digoxin levels in the body by slowing its elimination. This drug interaction requires careful consideration for patients taking both medications.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Hypertension in women: the role of progesterone and aldosterone.

    Climacteric : the journal of the International Menopause Society·2010
    Same author

    A new oscillometric method for pulse wave analysis: comparison with a common tonometric method.

    Journal of human hypertension·2010
    Same author

    [Arteriell wall-stiffness: a new important cardiovascular risk factor].

    Wiener medizinische Wochenschrift (1946)·2008
    Same author

    [Health care costs of multiple sclerosis in Austria. Cross-sectional study including consideration of quality of life].

    Der Nervenarzt·2004
    Same author

    Blood pressure characteristics of hypertensive patients in Austria as determined by self-monitoring (SCREEN-II).

    Blood pressure·2003
    Same author

    Prevalence of multiple sclerosis in Austria. Results of a nationwide survey.

    Neuroepidemiology·2002
    Same journal

    Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

    Clinical pharmacology and therapeutics·2026
    Same journal

    From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI.

    Clinical pharmacology and therapeutics·2026
    Same journal

    The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Cardiovascular medicine

    Background:

    • Diltiazem is a calcium antagonist used for cardiovascular conditions.
    • Digoxin is a cardiac glycoside used to treat heart failure and arrhythmias.

    Purpose of the Study:

    • To investigate the pharmacokinetic interaction between diltiazem and digoxin.
    • To determine the effect of diltiazem on digoxin plasma concentrations and elimination.

    Main Methods:

    • A randomized crossover trial was conducted in 24 healthy male subjects.
    • Subjects were studied under steady-state conditions for both drugs.

    Main Results:

    • Diltiazem increased steady-state plasma digoxin concentration and AUC by 22.4%.
    • Elimination half-life (t1/2) of digoxin prolonged from 36.2 to 44.5 hours.

    Related Experiment Videos

  • Total digoxin clearance decreased from 146.6 to 107.9 ml/min.
  • Renal clearance reduction was not statistically significant.
  • Diltiazem pharmacokinetics were unaffected by concurrent digoxin administration.

    • Conclusions:

    • Diltiazem significantly alters digoxin pharmacokinetics, leading to increased plasma concentrations.
    • The interaction is primarily due to impaired digoxin clearance and prolonged elimination.
    • Concurrent use of diltiazem and digoxin necessitates monitoring for potential digoxin toxicity.